Given that the US continues making unprecedented adjustments to its immunization guidelines, one figure has emerged in a surprising turn: Dr. Tracy Beth Høeg, a US-based physician and public health researcher who first made her name by expressing skepticism about coronavirus vaccines in the global health crisis and has concentrated on potential deaths following Covid immunization in her brief tenure at the FDA.
Planned Overhauls to Childhood Immunization Schedule
Public health authorities planned to unveil sweeping changes to the childhood vaccine schedule recently, aligning the US with the Danish immunization schedule, sources say – a substantial departure that would place the US at odds with many the global community with little proof for improved outcomes. The announcement has been pushed back until the next year.
In place of Vinay Prasad, Dr. Høeg is set to speak at the meeting. She was just designated interim head of the FDA’s drug evaluation center, the fifth appointee to lead the office this calendar year.
A Shift at the Regulatory Body
The acting appointment could signify a tighter collaboration between the pharmaceutical and biologics branches as Høeg and Prasad consolidate power at the regulatory agency – and it signals a increased emphasis upon reevaluating long-standing vaccines at the FDA.
Dr. Høeg has frequently advocated for halting certain childhood vaccine recommendations in the US to become more in line with Denmark, a nation with nationalized medicine and a citizenry roughly the size of the state of Wisconsin.
To date statements, she has kept her attention on immunizations – typically the domain of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.
Doubts Over Background
Dr. Høeg has little discernible background in medication creation, regulation or leadership, which has been standard for former directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the agency head and CBER since earlier this year.
“It seems she lacks to have any of the qualifications” for running the CDER, stated Jonathan Howard. “She has not conducted a clinical trial. She is not versed in managing a large organization. She lacks background in industry regulation.”
Previous directors of the center would “be deeply familiar with legal statutes and the research of medication creation”, commented Dr. Janet Woodcock. “Clearly, she doesn’t have the sort of resume that prior appointees who ran the center have had.”
The drug center has an enormous workload at the agency, Woodcock emphasized.
“Everybody just zeroes in on the innovative therapies, but the off-patent medication office authorizes thousands of generic medications. There’s a biosimilars division, OTC medication office and more, and each of these need to be looked after,” Woodcock explained. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to come back to haunt you.”
There is also, a significant administrative element to the job, which supervises in excess of 5,000 employees. “It’s a massive administrative position, if you execute it properly,” she said.
Agency Reaction and Contentious Programs
In response to inquiries about Dr. Høeg's qualifications and whether this appointment represents more teamwork among regulatory chiefs on vaccines, a representative said that the “concerns stem from incorrect presumptions”.
“This background is consistent with the responsibilities of her position,” the representative said, noting the months Dr. Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and immunization monitoring”.
In her interim role, Dr. Høeg assumes responsibility for the commissioner’s new expedited review system, a contentious expedited medication authorization process that apparently concerned her predecessors. “How are these therapies being selected for this fast-track system? Who makes the decisions?” Dr. Howard said. “There’s a lot of lack of transparency going on at the FDA right now.”
In general, he remarked, “the Food and Drug Administration looks to be trending towards less stringent oversight of most medications, with the exception of shots.”
Public History on Immunizations
With immunizations, Dr. Høeg has a more documented, if troubling, track record, Howard said. She published a analysis using unverified public submissions to assess the frequency of myocarditis after Covid vaccination. She consulted for the state of Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to indicate COVID-19 vaccines are pose a greater threat than they are.
Included in her “policy goals” for the new federal leadership featured changing guidelines for new vaccines and halting “non-essential” vaccines, she remarked following the vote on a podcast. At the agency, Dr. Høeg has reportedly floated the idea of excluding adolescent males from receiving Covid vaccinations.
“She’s an thorough true believer who starts off with her conclusions and reverse-engineers to accommodate the data in a very disingenuous, untruthful way,” Howard stated.
Taking Control and a “Push for Payback”
Høeg became part of fellow skeptics, {like|
